Richard Keefe - Publications

Affiliations: 
Duke Medical School, Durham, NC, United States 

314 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Williamson DJ, Nuechterlein KH, Tishler T, Ventura J, Ellingson BM, Turkoz I, Keefe RSE, Alphs L. Dispersion of cognitive performance test scores on the MATRICS Consensus Cognitive Battery: A different perspective. Schizophrenia Research. Cognition. 30: 100270. PMID 36111288 DOI: 10.1016/j.scog.2022.100270  0.384
2022 Seccomandi B, Agbedjro D, Keefe RSE, Galderisi S, Fiszdon J, Mucci A, Wykes T, Cella M. Evaluating how treatment adherence influences cognitive remediation outcomes. Behaviour Research and Therapy. 158: 104186. PMID 36096075 DOI: 10.1016/j.brat.2022.104186  0.367
2022 Atkins AS, Kraus MS, Welch M, Yuan Z, Stevens H, Welsh-Bohmer KA, Keefe RSE. Remote self-administration of digital cognitive tests using the Brief Assessment of Cognition: Feasibility, reliability, and sensitivity to subjective cognitive decline. Frontiers in Psychiatry. 13: 910896. PMID 36090378 DOI: 10.3389/fpsyt.2022.910896  0.654
2021 Eskridge CLM, Hochberger WC, Kaseda ET, Lencer R, Reilly JL, Keedy SK, Keefe RSE, Pearlson GD, Keshavan MS, Tamminga CA, Sweeney JA, Hill SK. Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders. Schizophrenia Research. 236: 54-60. PMID 34392106 DOI: 10.1016/j.schres.2021.07.036  0.412
2021 Turner TH, Atkins A, Keefe RSE. Virtual Reality Functional Capacity Assessment Tool (VRFCAT-SL) in Parkinson's Disease. Journal of Parkinson's Disease. PMID 34334421 DOI: 10.3233/JPD-212688  0.61
2021 Eum S, Hill SK, Alliey-Rodriguez N, Stevenson JM, Rubin LH, Lee AM, Mills LJ, Reilly JL, Lencer R, Keedy SK, Ivleva E, Keefe RSE, Pearlson GD, Clementz BA, Tamminga CA, et al. Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 34145405 DOI: 10.1038/s41386-021-01057-8  0.362
2021 Fleischhacker WW, Podhorna J, Gröschl M, Hake S, Zhao Y, Huang S, Keefe RSE, Desch M, Brenner R, Walling DP, Mantero-Atienza E, Nakagome K, Pollentier S. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. The Lancet. Psychiatry. 8: 191-201. PMID 33610228 DOI: 10.1016/S2215-0366(20)30513-7  0.427
2021 Seccomandi B, Agbedjro D, Bell M, Keefe RSE, Keshavan M, Galderisi S, Fiszdon J, Mucci A, Cavallaro R, Ojeda N, Peña J, Müller D, Roder V, Wykes T, Cella M. Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. Schizophrenia Research. 228: 29-35. PMID 33429151 DOI: 10.1016/j.schres.2020.11.060  0.402
2020 Seccomandi B, Agbedjro D, Bell M, Keefe RSE, Keshavan M, Galderisi S, Fiszdon J, Mucci A, Cavallaro R, Bechi M, Ojeda N, Peña J, Wykes T, Cella M. Can IQ moderate the response to cognitive remediation in people with schizophrenia? Journal of Psychiatric Research. 133: 38-45. PMID 33307353 DOI: 10.1016/j.jpsychires.2020.12.013  0.393
2020 Lim K, Smucny J, Barch DM, Lam M, Keefe RSE, Lee J. Cognitive Subtyping in Schizophrenia: A Latent Profile Analysis. Schizophrenia Bulletin. PMID 33098300 DOI: 10.1093/schbul/sbaa157  0.446
2020 Harvey PD, Horan WP, Atkins AS, Stevens H, Welch M, Yuan J, Patterson TL, Narasimhan M, Keefe RSE. Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures. Schizophrenia Research. PMID 32928621 DOI: 10.1016/J.Schres.2020.08.010  0.715
2020 Lindenmayer JP, Goldring A, Borne S, Khan A, Keefe RSE, Insel BJ, Thanju A, Ljuri I, Foreman B. Assessing instrumental activities of daily living (iADL) with a game-based assessment for individuals with schizophrenia. Schizophrenia Research. PMID 32690346 DOI: 10.1016/J.Schres.2020.07.001  0.338
2020 Keefe RSE, Green MF, Harvey PD. Requisite Skills and the Meaningful Measurement of Cognition. Jama Psychiatry. PMID 32639514 DOI: 10.1001/Jamapsychiatry.2020.1618  0.464
2020 Goldberg TE, Harvey PD, Devanand DP, Keefe RSE, Gomar JJ. Development of an UPSA Short Form for Use in Longitudinal Studies in the Early Alzheimer's Disease Spectrum. The Journal of Prevention of Alzheimer's Disease. 7: 179-183. PMID 32463071 DOI: 10.14283/jpad.2019.51  0.44
2020 Kilciksiz CM, Keefe R, Benoit J, Öngür D, Torous J. Verbal memory measurement towards digital perspectives in first-episode psychosis: A review. Schizophrenia Research. Cognition. 21: 100177. PMID 32322540 DOI: 10.1016/J.Scog.2020.100177  0.474
2020 Kraus MS, Gold JM, Barch DM, Walker TM, Chun CA, Buchanan RW, Csernansky JG, Goff DC, Green MF, Jarskog LF, Javitt DC, Kimhy D, Lieberman JA, McEvoy JP, Mesholam-Gately RI, ... ... Keefe RSE, et al. The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures. Schizophrenia Research. Cognition. 19: 100161. PMID 31832342 DOI: 10.1016/J.Scog.2019.100161  0.378
2020 Salgado JV, Carvalhaes CFR, Pires AM, Neves MCLD, Cruz BF, Cardoso CS, Lauar H, Teixeira AL, Keefe RSE. Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS). Dementia & Neuropsychologia. 1: 260-265. PMID 29213399 DOI: 10.1590/S1980-57642008DN10300007  0.467
2020 Lindenmayer J, Khan A, Harvey P, Keefe R, Liharska L, Yavorsky C, Seddo M. M120. IMPAIRED CLINICAL INSIGHT AS A PREDICTOR OF RELAPSE IN SCHIZOPHRENIA Schizophrenia Bulletin. 46: S180-S181. DOI: 10.1093/Schbul/Sbaa030.432  0.571
2019 Rakesh G, Mischel NA, Luber B, Keefe RSE, Emory S, Lisanby SH, Szabo ST. Theta Burst for Cognitive Remediation in Schizophrenia: A Case Series and Feasibility Study. The Journal of Ect. PMID 31652174 DOI: 10.1097/Yct.0000000000000625  0.42
2019 Harvey PD, Khan A, Atkins A, Walker TM, Keefe RSE. Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS). Schizophrenia Research. PMID 31196736 DOI: 10.1016/J.Schres.2019.05.040  0.764
2019 Ventura J, Welikson T, Ered A, Subotnik KL, Keefe RSE, Hellemann GS, Nuechterlein KH. Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning. Early Intervention in Psychiatry. PMID 31183960 DOI: 10.1111/Eip.12831  0.451
2019 Keefe RSE. Why are there no approved treatments for cognitive impairment in schizophrenia? World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 18: 167-168. PMID 31059617 DOI: 10.1002/wps.20648  0.439
2019 Mahncke HW, Kim SJ, Rose A, Stasio C, Buckley P, Caroff S, Duncan E, Yasmin S, Jarskog LF, Lamberti JS, Nuechterlein K, Strassnig M, Velligan D, Ventura J, Walker T, ... ... Keefe RSE, et al. Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. Schizophrenia Research. PMID 30930034 DOI: 10.1016/J.Schres.2019.03.006  0.369
2019 Harvey PD, Khan A, Atkins A, Keefe RS. Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes. Psychiatry Research. PMID 30679049 DOI: 10.1016/J.Psychres.2019.01.045  0.693
2019 Harvey P, Khan A, Atkins A, Keefe R. O5.7. VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT IN PATIENTS WITH SCHIZOPHRENIA: CORRELATES OF PERFORMANCE OF SOLITARY AND SOCIALLY RELEVANT TASKS Schizophrenia Bulletin. 45: S175-S175. DOI: 10.1093/Schbul/Sbz021.216  0.721
2019 Podhorna J, Hake S, Groeschl M, Pollentier S, Atkins A, Keefe R. S27. EFFICACY, SAFETY, AND PHARMACOKINETICS OF BI 425809 ONCE DAILY IN PATIENTS WITH SCHIZOPHRENIA: METHODOLOGY OF A RANDOMIZED TRIAL Schizophrenia Bulletin. 45: S315-S316. DOI: 10.1093/Schbul/Sbz020.572  0.67
2019 Welsh-Bohmer KA, Atkins AS, Plassman BL, Khan A, Chiang C, Culp M, O'Neil J, Walter R, Haneline S, Arbuckle J, Brewster S, Maruyama Y, Swanson T, Hayden KM, Romero H, ... Keefe RS, et al. O4-11-02: DEFINING COGNITION IN PRE-DEMENTIA CLINICAL TRIALS: BASELINE NEUROPSYCHOLOGICAL DATA FROM THE TOMMORROW STUDY Alzheimer's & Dementia. 15: P1262-P1262. DOI: 10.1016/J.Jalz.2019.06.4801  0.616
2019 Gomar JJ, Harvey PD, Devanand DP, Keefe RS, Goldberg TE. P2-463: DEVELOPMENT OF AN UPSA SHORT FORM FOR USE IN LONGITUDINAL STUDIES IN THE EARLY ALZHEIMER'S DISEASE SPECTRUM Alzheimer's & Dementia. 15: P794-P794. DOI: 10.1016/J.Jalz.2019.06.2870  0.333
2018 Atkins AS, Khan A, Ulshen D, Vaughan A, Balentin D, Dickerson H, Liharska LE, Plassman B, Welsh-Bohmer K, Keefe RSE. Assessment of Instrumental Activities of Daily Living in Older Adults with Subjective Cognitive Decline Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). The Journal of Prevention of Alzheimer's Disease. 5: 216-234. PMID 30298179 DOI: 10.14283/jpad.2018.28  0.634
2018 Kraus MS, Walker TM, Jarskog LF, Millet RA, Keefe RSE. Basic auditory processing deficits and their association with auditory emotion recognition in schizophrenia. Schizophrenia Research. PMID 30268821 DOI: 10.1016/j.schres.2018.08.031  0.328
2018 Romero HR, Monsch AU, Hayden KM, Plassman BL, Atkins AS, Keefe RSE, Brewster S, Chiang C, O'Neil J, Runyan G, Atkinson MJ, Crawford S, Budur K, Burns DK, Welsh-Bohmer KA. TOMMORROW neuropsychological battery: German language validation and normative study. Alzheimer's & Dementia (New York, N. Y.). 4: 314-323. PMID 30094331 DOI: 10.1016/J.Trci.2018.06.009  0.632
2018 Lam M, Lee J, Rapisarda A, See YM, Yang Z, Lee SA, Abdul-Rashid NA, Kraus M, Subramaniam M, Chong SA, Keefe RSE. Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis. Jama Psychiatry. PMID 30046827 DOI: 10.1001/jamapsychiatry.2018.1668  0.302
2018 Fava M, Mahableshwarkar AR, Jacobson W, Zhong W, Keefe RS, Olsen CK, Jaeger J. What is the overlap between subjective and objective cognitive impairments in MDD? Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists. 30: 176-184. PMID 30028891  0.308
2018 Keefe RSE, Harvey PD, Khan A, Saoud JB, Staner C, Davidson M, Luthringer R. Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. The Journal of Clinical Psychiatry. 79. PMID 29873956 DOI: 10.4088/Jcp.17M11753  0.606
2018 Yang Z, Lim K, Lam M, Keefe R, Lee J. Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis. Schizophrenia Research. PMID 29804925 DOI: 10.1016/J.Schres.2018.05.024  0.367
2018 Brown D, Nakagome K, Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenberg R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Schizophrenia Bulletin. PMID 29718385 DOI: 10.1093/Schbul/Sby049  0.417
2018 Shafee R, Nanda P, Padmanabhan JL, Tandon N, Alliey-Rodriguez N, Kalapurakkel S, Weiner DJ, Gur RE, Keefe RSE, Hill SK, Bishop JR, Clementz BA, Tamminga CA, Gershon ES, Pearlson GD, et al. Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. Translational Psychiatry. 8: 78. PMID 29643358 DOI: 10.1038/S41398-018-0124-8  0.594
2018 Xavier RM, Dungan JR, Keefe RSE, Vorderstrasse A. Polygenic signal for symptom dimensions and cognitive performance in patients with chronic schizophrenia. Schizophrenia Research. Cognition. 12: 11-19. PMID 29552508 DOI: 10.1016/j.scog.2018.01.001  0.832
2018 Seccomandi B, Agbedjro D, Bell M, Keefe R, Keshavan M, Galderisi S, Medalia A, Fiszdon J, Maj M, Mucci A, Cavallato R, Wykes T, Cella M. T206. DOES AGE INFLUENCE RESPONSE TO COGNITIVE REMEDIATION? Schizophrenia Bulletin. 44: S196-S197. DOI: 10.1093/Schbul/Sby016.482  0.33
2018 Khan A, Liharska L, Harvey P, Atkins A, Keefe R, Ulshen D. T111. PANSS NEGATIVE SYMPTOM DIMENSIONS ACROSS GEOGRAPHICAL REGIONS: IMPLICATIONS FOR SOCIAL, LINGUISTIC AND CULTURAL CONSISTENCY Schizophrenia Bulletin. 44: S159-S159. DOI: 10.1093/Schbul/Sby016.387  0.655
2018 Ventura J, Welikson T, Subotnik KL, Ered A, Keefe R, Hellemann GH, Nuechterlein KH. T59. Virtual Realty Assessment Of Functional Capacity In Early Schizophrenia: Associations With Neurocognition, Functional Capacity Performance, And Daily Functioning Schizophrenia Bulletin. 44. DOI: 10.1093/Schbul/Sby016.335  0.435
2018 Sand M, Daniels K, Keefe R, Cordes J, Brenner R, Riesenberg R, Brown D, Nakagome K, Gründer G, Carter K, Walling D, Wang L. Effect of BI 409306 on Positive and Negative Syndrome Scale in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial Biological Psychiatry. 83. DOI: 10.1016/J.Biopsych.2018.02.542  0.388
2017 Khan A, Liharska L, Harvey PD, Atkins A, Ulshen D, Keefe RSE. Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency. Innovations in Clinical Neuroscience. 14: 30-40. PMID 29410935  0.678
2017 Harvey PD, Khan A, Keefe RSE. Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience. Innovations in Clinical Neuroscience. 14: 18-22. PMID 29410933  0.42
2017 Xavier RM, Vorderstrasse A, Keefe RSE, Dungan JR. Genetic correlates of insight in schizophrenia. Schizophrenia Research. PMID 29054485 DOI: 10.1016/j.schres.2017.10.021  0.793
2017 Ang MS, Abdul Rashid NA, Lam M, Rapisarda A, Kraus M, Keefe RSE, Lee J. The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia. Journal of Clinical Psychopharmacology. PMID 29016375 DOI: 10.1097/JCP.0000000000000790  0.452
2017 Blokland GAM, Del Re EC, Mesholam-Gately RI, Jovicich J, Trampush JW, Keshavan MS, DeLisi LE, Walters JTR, Turner JA, Malhotra AK, Lencz T, Shenton ME, Voineskos AN, Rujescu D, Giegling I, ... ... Keefe RSE, et al. The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project. Schizophrenia Research. PMID 28982554 DOI: 10.1016/J.Schres.2017.09.024  0.345
2017 Cella M, Stahl D, Morris S, Keefe RSE, Bell MD, Wykes T. Effects of cognitive remediation on negative symptoms dimensions: exploring the role of working memory. Psychological Medicine. 1-9. PMID 28866985 DOI: 10.1017/S0033291717000757  0.362
2017 Xavier RM, Pan W, Dungan JR, Keefe RSE, Vorderstrasse A. Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia. Schizophrenia Research. PMID 28693755 DOI: 10.1016/J.Schres.2017.07.002  0.826
2017 Keefe RSE, Davis VG, Harvey PD, Atkins AS, Haig GM, Hagino O, Marder S, Hilt DC, Umbricht D. Placebo Response and Practice Effects in Schizophrenia Cognition Trials. Jama Psychiatry. PMID 28636694 DOI: 10.1001/Jamapsychiatry.2017.1574  0.754
2017 Mazhari S, Ghafaree-Nejad AR, Soleymani-Zade S, Keefe RSE. Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia. Asian Journal of Psychiatry. 27: 12-15. PMID 28558882 DOI: 10.1016/j.ajp.2017.02.007  0.469
2017 Lam M, Wang M, Huang W, Eng GK, Rapisarda A, Kraus M, Kang S, Keefe RSE, Lee J. Establishing the Brief Assessment of Cognition - Short form. Journal of Psychiatric Research. 93: 1-11. PMID 28549241 DOI: 10.1016/j.jpsychires.2017.05.006  0.414
2017 Hochberger WC, Combs T, Reilly JL, Bishop JR, Keefe RSE, Clementz BA, Keshavan MS, Pearlson GD, Tamminga CA, Hill SK, Sweeney JA. Deviation from expected cognitive ability across psychotic disorders. Schizophrenia Research. PMID 28545944 DOI: 10.1016/J.Schres.2017.05.019  0.396
2017 Georgiades A, Davis VG, Atkins AS, Khan A, Walker TW, Loebel A, Haig G, Hilt DC, Dunayevich E, Umbricht D, Sand M, Keefe RSE. Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophrenia Research. PMID 28433500 DOI: 10.1016/J.Schres.2017.03.040  0.69
2017 Eum S, Hill SK, Rubin LH, Carnahan RM, Reilly JL, Ivleva EI, Keedy SK, Tamminga CA, Pearlson GD, Clementz BA, Gershon ES, Keshavan MS, Keefe RS, Sweeney JA, Bishop JR. Cognitive burden of anticholinergic medications in psychotic disorders. Schizophrenia Research. PMID 28390849 DOI: 10.1016/J.Schres.2017.03.034  0.346
2017 Keefe RS, Kahn RS. Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia. Jama Psychiatry. PMID 28329400 DOI: 10.1001/Jamapsychiatry.2017.0312  0.41
2017 Bishop J, Hill S, Mills L, Alliey-Rodriguez N, Reilly J, Shaffee R, McCarroll S, Keefe R, Pearlson G, Clementz B, Tamminga C, Keshavan M, Gershon E, Sweeney J. M94. Genetic Analyses of Cognitive Performance in Psychotic Disorders From the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Consortium Schizophrenia Bulletin. 43: S245-S245. DOI: 10.1093/Schbul/Sbx022.089  0.45
2017 Atkins A, Tseng T, Vaughan A, Harvey P, Narasimhan M, Patterson T, Khan A, Keefe R. M25. Development and Validation of the Brief Assessment of Validation in Schizophrenia (BAC-App) Schizophrenia Bulletin. 43: S220-S220. DOI: 10.1093/Schbul/Sbx022.024  0.726
2017 Schooler N, Khan A, Keefe R, Robinson D, Kane J. 43. Cognitive Functioning in First-Episode Psychosis:_x000B_ Comparison of a 2-Year Coordinated Specialty Care Program to Community Care Schizophrenia Bulletin. 43. DOI: 10.1093/Schbul/Sbx021.062  0.307
2017 Marx C, Naylor J, Kilts J, Allan T, Smith K, Szabo S, Wagner R, Buchanan R, Keefe R, Shampine L. 19. Randomized Controlled Trial of a Neurosteroid Intervention in Schizophrenia Schizophrenia Bulletin. 43: S14-S14. DOI: 10.1093/Schbul/Sbx021.038  0.435
2017 Atkins AS, Khan A, Welsh-Bohmer KA, Plassman BL, Randolph C, Harrison J, Keefe RS. EXPANDING THE BRIEF ASSESSMENT OF COGNITION (BAC-APP) FOR ASSESSMENT OF COGNITION IN AGING: INITIAL FINDINGS FROM AN ONGOING NORMATIVE STUDY Alzheimer's & Dementia. 13: P1574-P1575. DOI: 10.1016/J.Jalz.2017.07.741  0.643
2017 Lam M, Keefe R, Liu JJ, Lee J. Pleiotropic Effects of Schizophrenia And Cognitive LOCI: A Meta-Analytic Approach European Neuropsychopharmacology. 27. DOI: 10.1016/J.Euroneuro.2016.09.432  0.537
2017 Lam M, Keefe R, Liu J, Lee J. 700. Genetic Overlaps between Schizophrenia and Cognition in Asia Biological Psychiatry. 81. DOI: 10.1016/J.Biopsych.2017.02.767  0.515
2016 Kraus M, Rapisarda A, Lam M, Thong JYJ, Lee J, Subramaniam M, Collinson SL, Chong SA, Keefe RSE. Disrupted latent inhibition in individuals at ultra high-risk for developing psychosis. Schizophrenia Research. Cognition. 6: 1-8. PMID 28740818 DOI: 10.1016/j.scog.2016.07.003  0.356
2016 Atkins AS, Davis V, Tseng T, Vaughan A, Harvey P, Patterson T, Narasimhan M, Keefe RS. Validation of the tablet-administered Brief Assessment of Cognition (BAC App). Schizophrenia Research. PMID 27771201 DOI: 10.1016/J.Schres.2016.10.010  0.718
2016 Reilly JL, Hill SK, Gold JM, Keefe RS, Clementz BA, Gershon E, Keshavan MS, Pearlson G, Tamminga CA, Sweeney JA. Impaired Context Processing is Attributable to Global Neuropsychological Impairment in Schizophrenia and Psychotic Bipolar Disorder. Schizophrenia Bulletin. PMID 27306316 DOI: 10.1093/Schbul/Sbw081  0.388
2016 Cruz BF, Resende CB, Carvalhaes CF, Cardoso CS, Teixeira AL, Keefe RS, Rocha FL, Salgado JV. Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms. Revista Brasileira De Psiquiatria (Sao Paulo, Brazil : 1999). 0. PMID 27304257 DOI: 10.1590/1516-4446-2015-1776  0.426
2016 Keefe RS, Davis VG, Atkins AS, Vaughan A, Patterson T, Narasimhan M, Harvey PD. Validation of a Computerized test of Functional Capacity. Schizophrenia Research. PMID 27091656 DOI: 10.1016/J.Schres.2016.03.038  0.752
2016 Lim J, Lee SA, Lam M, Rapisarda A, Kraus M, Keefe RS, Lee J. The relationship between negative symptom subdomains and cognition. Psychological Medicine. 1-9. PMID 27087476 DOI: 10.1017/S0033291716000726  0.36
2016 Kantrowitz JT, Sharif Z, Medalia A, Keefe RS, Harvey P, Bruder G, Barch DM, Choo T, Lee S, Lieberman JA. A multicenter, rater-blinded, randomized controlled study of auditory processing-focused cognitive remediation combined with open-label lurasidone in patients with schizophrenia and schizoaffective disorder. The Journal of Clinical Psychiatry. PMID 27035157 DOI: 10.4088/Jcp.15M09998  0.551
2016 Keefe RS, Reichenberg A. Predicting Schizophrenia. Jama Psychiatry. 73: 441-2. PMID 27028053 DOI: 10.1001/jamapsychiatry.2016.0138  0.337
2016 Kraus M, Rapisarda A, Lam M, Thong JYJ, Lee J, Subramaniam M, Collinson SL, Chong SA, Keefe RSE. Disrupted latent inhibition in individuals at ultra high-risk for developing psychosis Schizophrenia Research: Cognition. 6: 1-8. DOI: 10.1016/j.scog.2016.07.003  0.356
2016 Khan A, Atkins AS, Stroescu I, Davis V, Williamson T, Mozley LH, Voss T, McMahon KB, Keefe RS. P4-291: Assessing the Impact of a Centralized Data Review on the Reliability of the Alzheimer’S Disease Assessment Scale-Cognitive (ADAS-COG) Alzheimer's & Dementia. 12: P1145-P1145. DOI: 10.1016/J.Jalz.2016.07.033  0.617
2015 Hochberger WC, Hill SK, Nelson CL, Reilly JL, Keefe RS, Pearlson GD, Keshavan MS, Tamminga CA, Clementz BA, Sweeney JA. Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives. Schizophrenia Research. PMID 26645510 DOI: 10.1016/J.Schres.2015.11.022  0.429
2015 Atkins AS, Stroescu I, Spagnola NB, Davis VG, Patterson TD, Narasimhan M, Harvey PD, Keefe RS. Assessment of Age-Related Differences in Functional Capacity Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). The Journal of Prevention of Alzheimer's Disease. 2: 121-127. PMID 26618145 DOI: 10.14283/jpad.2015.61  0.679
2015 Keefe RS, Harvey PD. Understanding Symbol Coding in Schizophrenia. Biological Psychiatry. 78: 744-6. PMID 26542742 DOI: 10.1016/J.Biopsych.2015.09.005  0.55
2015 McCleery A, Green MF, Hellemann GS, Baade LE, Gold JM, Keefe RS, Kern RS, Mesholam-Gately RI, Seidman LJ, Subotnik KL, Ventura J, Nuechterlein KH. Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB). Psychological Medicine. 1. PMID 26537981 DOI: 10.1017/S0033291715002433  0.412
2015 Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, Davidson M, Lombardo I, Bowie CR, Buchanan RW, Bugarski-Kirola D, Carpenter WT, Csernansky JT, Dago PL, Durand DM, et al. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophrenia Bulletin. PMID 26362273 DOI: 10.1093/Schbul/Sbv111  0.536
2015 Keefe RS, Meltzer HA, Dgetluck N, Gawryl M, Koenig G, Moebius HJ, Lombardo I, Hilt DC. Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 3053-60. PMID 26089183 DOI: 10.1038/npp.2015.176  0.408
2015 Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman SM, Russ JC, ... Keefe RS, et al. Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms. Journal of Clinical Psychopharmacology. 35: 374-81. PMID 26082974 DOI: 10.1097/Jcp.0000000000000345  0.397
2015 Iwata Y, Nakajima S, Suzuki T, Keefe RS, Plitman E, Chung JK, Caravaggio F, Mimura M, Graff-Guerrero A, Uchida H. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. Molecular Psychiatry. PMID 26077694 DOI: 10.1038/Mp.2015.68  0.397
2015 Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC. Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. Schizophrenia Bulletin. PMID 26071208 DOI: 10.1093/schbul/sbv072  0.345
2015 Araújo GE, Resende CB, Cardoso AC, Teixeira AL, Keefe RS, Salgado JV. Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition in Schizophrenia). Clinics (Sao Paulo, Brazil). 70: 278-82. PMID 26017795 DOI: 10.6061/clinics/2015(04)10  0.43
2015 Kristian Hill S, Buchholz A, Amsbaugh H, Reilly JL, Rubin LH, Gold JM, Keefe RS, Pearlson GD, Keshavan MS, Tamminga CA, Sweeney JA. Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment. Schizophrenia Research. 166: 310-5. PMID 26008884 DOI: 10.1016/J.Schres.2015.05.018  0.318
2015 Harvey PD, Keefe RS. Methods for delivering and evaluating the efficacy of cognitive enhancement. Handbook of Experimental Pharmacology. 228: 5-25. PMID 25977078 DOI: 10.1007/978-3-319-16522-6_1  0.496
2015 McCleery A, Green MF, Hellemann GS, Baade LE, Gold JM, Keefe RS, Kern RS, Mesholam-Gately RI, Seidman LJ, Subotnik KL, Ventura J, Nuechterlein KH. Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB). Psychological Medicine. 1-10. PMID 25916421 DOI: 10.1017/S0033291715000641  0.431
2015 Lim J, Rekhi G, Rapisarda A, Lam M, Kraus M, Keefe RS, Lee J. Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS). Schizophrenia Research. 164: 8-14. PMID 25818728 DOI: 10.1016/j.schres.2015.03.007  0.35
2015 Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, et al. A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia Research. 164: 136-42. PMID 25728831 DOI: 10.1016/J.Schres.2015.01.041  0.403
2015 Healey KM, Combs DR, Gibson CM, Keefe RS, Roberts DL, Penn DL. Observable Social Cognition--A Rating Scale: an interview-based assessment for schizophrenia. Cognitive Neuropsychiatry. 20: 198-221. PMID 25675960 DOI: 10.1080/13546805.2014.999915  0.407
2015 Bauer IE, Keefe RS, Sanches M, Suchting R, Green CE, Soares JC. Evaluation of cognitive function in bipolar disorder using the Brief Assessment of Cognition in Affective Disorders (BAC-A). Journal of Psychiatric Research. 60: 81-6. PMID 25455513 DOI: 10.1016/j.jpsychires.2014.10.002  0.309
2015 Hill SK, Reilly JL, Ragozzino ME, Rubin LH, Bishop JR, Gur RC, Gershon ES, Tamminga CA, Pearlson GD, Keshavan MS, Keefe RS, Sweeney JA. Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study. Schizophrenia Bulletin. 41: 940-50. PMID 25194139 DOI: 10.1093/Schbul/Sbu130  0.35
2015 Lui S, Yao L, Xiao Y, Keedy SK, Reilly JL, Keefe RS, Tamminga CA, Keshavan MS, Pearlson GD, Gong Q, Sweeney JA. Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives. Psychological Medicine. 45: 97-108. PMID 25066779 DOI: 10.1017/S003329171400110X  0.338
2015 Keefe RS, Davis VG, Spagnola NB, Hilt D, Dgetluck N, Ruse S, Patterson TD, Narasimhan M, Harvey PD. Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 176-84. PMID 25028065 DOI: 10.1016/J.Euroneuro.2014.06.009  0.604
2015 Yasuhiro Kaneda M, Keefe RS. An abbreviated version of the brief assessment of cognition in schizophrenia (BACS) The European Journal of Psychiatry. 29: 131-134. DOI: 10.4321/S0213-61632015000200004  0.464
2015 Jacobson W, Olsen C, Mahableshwarkar A, Yinzhong C, Keefe R. P.2.h.012 Effect of vortioxetine on functional capacity in patients with major depressive disorder with self-reported cognitive dysfunction European Neuropsychopharmacology. 25. DOI: 10.1016/S0924-977X(15)30622-2  0.339
2015 Atkins AS, Stroescu I, Davis V, Williamson T, Boyd K, Mozley LH, Voss T, Budd-McMahon K, Keefe RS. P4-299: Impact of expert data review and centralized scoring on test-retest reliability of the adas-cog Alzheimer's & Dementia. 11: P899-P900. DOI: 10.1016/j.jalz.2015.08.129  0.556
2014 Ethridge LE, Soilleux M, Nakonezny PA, Reilly JL, Hill SK, Keefe RS, Gershon ES, Pearlson GD, Tamminga CA, Keshavan MS, Sweeney JA. Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit. Schizophrenia Research. 159: 491-8. PMID 25261042 DOI: 10.1016/J.Schres.2014.08.025  0.393
2014 Hufford MR, Davis VG, Hilt D, Dgetluck N, Geffen Y, Loebel A, Haig G, Santarelli L, Keefe RSE. Circadian rhythms in cognitive functioning among patients with schizophrenia: Impact on signal detection in clinical trials of potential pro-cognitive therapies Schizophrenia Research. 159: 205-210. PMID 25108773 DOI: 10.1016/j.schres.2014.07.018  0.391
2014 Ruse SA, Harvey PD, Davis VG, Atkins AS, Fox KH, Keefe RS. Virtual Reality Functional Capacity Assessment In Schizophrenia: Preliminary Data Regarding Feasibility and Correlations with Cognitive and Functional Capacity Performance. Schizophrenia Research. Cognition. 1: e21-e26. PMID 25083416 DOI: 10.1016/J.Scog.2014.01.004  0.747
2014 Keefe RSE. Cognition and motivation as treatment targets in schizophrenia Jama Psychiatry. 71: 987-988. PMID 25075711 DOI: 10.1001/jamapsychiatry.2014.1281  0.407
2014 Lam M, Collinson SL, Eng GK, Rapisarda A, Kraus M, Lee J, Chong SA, Keefe RS. Refining the latent structure of neuropsychological performance in schizophrenia. Psychological Medicine. 44: 3557-70. PMID 25066336 DOI: 10.1017/S0033291714001020  0.45
2014 Keefe RS, Fox KH, Davis VG, Kennel C, Walker TM, Burdick KE, Harvey PD. The Brief Assessment of Cognition In Affective Disorders (BAC-A):performance of patients with bipolar depression and healthy controls. Journal of Affective Disorders. 166: 86-92. PMID 25012414 DOI: 10.1016/J.Jad.2014.05.002  0.49
2014 Keefe RSE. The longitudinal course of cognitive impairment in schizophrenia: An examination of data from premorbid through posttreatment phases of illness Journal of Clinical Psychiatry. 75: 8-13. PMID 24919165 DOI: 10.4088/JCP.13065su1.02  0.45
2014 Rapisarda A, Kraus M, Tan YW, Lam M, Eng GK, Lee J, Subramaniam M, Collinson SL, Chong SA, Keefe RS. The continuous performance test, identical pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore. Schizophrenia Research. 156: 233-40. PMID 24819191 DOI: 10.1016/j.schres.2014.04.016  0.364
2014 Ruse SA, Davis VG, Atkins AS, Krishnan KR, Fox KH, Harvey PD, Keefe RS. Development of a virtual reality assessment of everyday living skills. Journal of Visualized Experiments : Jove. PMID 24798174 DOI: 10.3791/51405  0.744
2014 Yong E, Barbato M, Penn DL, Keefe RS, Woods SW, Perkins DO, Addington J. Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis. Psychiatry Research. 218: 39-43. PMID 24755041 DOI: 10.1016/J.Psychres.2014.04.003  0.324
2014 Graham KA, Keefe RS, Lieberman JA, Calikoglu AS, Lansing KM, Perkins DO. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. Early Intervention in Psychiatry. PMID 24612563 DOI: 10.1111/Eip.12122  0.331
2014 Mazhari S, Parvaresh N, Eslami Shahrbabaki M, Sadeghi MM, Nakhaee N, Keefe RS. Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls. Psychiatry and Clinical Neurosciences. 68: 160-6. PMID 24552637 DOI: 10.1111/pcn.12107  0.481
2014 Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, Santarelli L. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 39: 1568-77. PMID 24549101 DOI: 10.1038/npp.2014.17  0.409
2014 Reilly JL, Frankovich K, Hill S, Gershon ES, Keefe RS, Keshavan MS, Pearlson GD, Tamminga CA, Sweeney JA. Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories. Schizophrenia Bulletin. 40: 1011-21. PMID 24080895 DOI: 10.1093/Schbul/Sbt132  0.308
2014 Meier MH, Caspi A, Reichenberg A, Keefe RS, Fisher HL, Harrington H, Houts R, Poulton R, Moffitt TE. Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study. The American Journal of Psychiatry. 171: 91-101. PMID 24030246 DOI: 10.1176/Appi.Ajp.2013.12111438  0.448
2014 Bauer I, Keefe R, Suchting R, Green C, Zunta-Soares G, Soares J. The brief assessment of cognition in affective disorders (BAC-A): a new instrument for assessing cognitive functioning in bipolar disorder F1000research. 5. DOI: 10.7490/F1000Research.1095519.1  0.397
2014 Lam M, Collinson S, Eng GK, Rapisarda A, Kraus M, Lee J, Chong SA, Keefe R. Poster #M186 NEUROCOGNITIVE ARCHITECTURE OF SCHIZOPHRENIA Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70736-4  0.43
2014 Huang W, Lee J, Lam M, Rapisarda A, Kraus M, Keefe R. Poster #S188 THE ROLE OF COGNITIVE RESERVE IN PREDICTING NEUROPSYCHOLOGICAL OUTCOME IN SCHIZOPHRENIA Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70467-0  0.493
2014 Kelly DL, Sullivan KM, Wehring HJ, McEvoy JP, Keefe R, McMahon RP, Gold JM, Feldman S, Warfel C, Kearns AM, Osing J, Russ J, Vyas G, Richardson CM, August S, et al. Adjunctive Minocycline In Clozapine Treated Schizophrenia Patients Schizophrenia Research. 153. DOI: 10.1016/S0920-9964(14)70257-9  0.474
2014 Atkins AS, Keefe RS, Vaughan AW, Turcotte NM, Makeeva OA, Monsch AU, Frisoni GB, Parapini M, Melikyan ZA, Brewster S, O'Neil J, Schuster J, Lymboura M, Romero H, Hayden KM, et al. P3-255: CULTURAL ADAPTATION OF TRANSLATED NEUROCOGNITIVE ASSESSMENTS IN RUSSIA, SWITZERLAND AND ITALY: PILOT TESTING FOR A PROGRAM TO DELAY THE ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE Alzheimer's & Dementia. 10: P725-P726. DOI: 10.1016/J.Jalz.2014.05.1347  0.625
2013 Lee TS, Goh SJ, Quek SY, Phillips R, Guan C, Cheung YB, Feng L, Teng SS, Wang CC, Chin ZY, Zhang H, Ng TP, Lee J, Keefe R, Krishnan KR. A brain-computer interface based cognitive training system for healthy elderly: a randomized control pilot study for usability and preliminary efficacy. Plos One. 8: e79419. PMID 24260218 DOI: 10.1371/Journal.Pone.0079419  0.325
2013 Rashid NA, Lim J, Lam M, Chong SA, Keefe RS, Lee J. Unraveling the relationship between obesity, schizophrenia and cognition. Schizophrenia Research. 151: 107-12. PMID 24119725 DOI: 10.1016/j.schres.2013.09.020  0.318
2013 Meier MH, Shalev I, Moffitt TE, Kapur S, Keefe RS, Wong TY, Belsky DW, Harrington H, Hogan S, Houts R, Caspi A, Poulton R. Microvascular abnormality in schizophrenia as shown by retinal imaging. The American Journal of Psychiatry. 170: 1451-9. PMID 24030514 DOI: 10.1176/Appi.Ajp.2013.13020234  0.336
2013 Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TR, Caers I, Daniel DG, Dunayevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn RS, Kane JM, Keefe RS, et al. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research. 150: 328-33. PMID 24028744 DOI: 10.1016/J.Schres.2013.07.058  0.46
2013 Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for a change in focus. Jama Psychiatry. 70: 1107-12. PMID 23925787 DOI: 10.1001/Jamapsychiatry.2013.155  0.453
2013 Eng GK, Lam M, Bong YL, Subramaniam M, Bautista D, Rapisarda A, Kraus M, Lee J, Collinson SL, Chong SA, Keefe RS. Brief assessment of cognition in schizophrenia: normative data in an English-speaking ethnic Chinese sample. Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists. 28: 845-58. PMID 23912998 DOI: 10.1093/arclin/act060  0.407
2013 Hill SK, Reilly JL, Keefe RS, Gold JM, Bishop JR, Gershon ES, Tamminga CA, Pearlson GD, Keshavan MS, Sweeney JA. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. The American Journal of Psychiatry. 170: 1275-84. PMID 23771174 DOI: 10.1176/Appi.Ajp.2013.12101298  0.405
2013 Nutt D, Gispen-de Wied CC, Arango C, Keefe RS, Penadés R, Murphy DG, Robbins TW, Sahakian BJ. Cognition in schizophrenia: summary Nice Consultation Meeting 2012. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 769-78. PMID 23684476 DOI: 10.1016/J.Euroneuro.2013.03.005  0.45
2013 Vita A, Deste G, Barlati S, De Peri L, Giambra A, Poli R, Keefe RS, Sacchetti E. Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care. Schizophrenia Research. 146: 217-23. PMID 23510596 DOI: 10.1016/j.schres.2013.02.035  0.458
2013 Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 1245-52. PMID 23325325 DOI: 10.1038/Npp.2013.23  0.422
2013 Barbato M, Colijn MA, Keefe RS, Perkins DO, Woods SW, Hawkins KA, Christensen BK, Addington J. The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. Psychiatry Research. 206: 195-9. PMID 23159196 DOI: 10.1016/J.Psychres.2012.10.013  0.336
2013 Cruz BF, de Resende CB, Abreu MN, Rocha FL, Teixeira AL, Keefe RS, Salgado JV. How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS. Cognitive Neuropsychiatry. 18: 243-51. PMID 23145794 DOI: 10.1080/13546805.2012.730995  0.461
2013 Keefe RS, Harvey PD. Cognitive impairment in schizophrenia. Handbook of Experimental Pharmacology. 11-37. PMID 23027411 DOI: 10.1007/978-3-642-25758-2_2  0.477
2013 Ventura J, Reise SP, Keefe RS, Hurford IM, Wood RC, Bilder RM. The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition. Schizophrenia Bulletin. 39: 583-91. PMID 22328641 DOI: 10.1093/Schbul/Sbs001  0.361
2013 Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. Schizophrenia Bulletin. 39: 564-74. PMID 22290266 DOI: 10.1093/schbul/sbr189  0.306
2013 Keefe RSE, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: What have we learned so far? Schizophrenia Bulletin. 39: 417-435. PMID 22114098 DOI: 10.1093/schbul/sbr153  0.462
2013 Hufford M, Davis V, Dgetluck N, Gawryl M, Hilt D, Rappaport A, Keefe R. Circadian rhythms in cognitive functioning: Impact on signal detection in clinical trials of pro-cognitive therapies Alzheimers & Dementia. 9: 298. DOI: 10.1016/J.Jalz.2013.05.607  0.379
2012 Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson M. BL-1020, a new γ-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study Journal of Clinical Psychiatry. 73. PMID 23059159 DOI: 10.4088/Jcp.12M07642  0.509
2012 Kahn PV, Walker TM, Williams TS, Cornblatt BA, Mohs RC, Keefe RS. Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study. Schizophrenia Research. 142: 153-8. PMID 23040735 DOI: 10.1016/j.schres.2012.09.009  0.409
2012 Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, George Awad A, Keefe RS, Naber D. Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia. Psychiatry Research. 200: 835-42. PMID 22841345 DOI: 10.1016/j.psychres.2012.05.005  0.363
2012 Keefe RS, Vinogradov S, Medalia A, Buckley PF, Caroff SN, D'Souza DC, Harvey PD, Graham KA, Hamer RM, Marder SM, Miller DD, Olson SJ, Patel JK, Velligan D, Walker TM, et al. Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. The Journal of Clinical Psychiatry. 73: 1016-22. PMID 22687548 DOI: 10.4088/Jcp.11M07100  0.377
2012 Weiser M, Gershon AA, Rubinstein K, Petcu C, Ladea M, Sima D, Podea D, Keefe RS, Davis JM. A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research. 138: 35-8. PMID 22483162 DOI: 10.1016/j.schres.2012.02.014  0.418
2012 Keefe RS, Kraus MS. Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia. The American Journal of Psychiatry. 169: 354-7. PMID 22476674 DOI: 10.1176/appi.ajp.2012.12010042  0.396
2012 Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophrenia Research. 136: 25-31. PMID 22169248 DOI: 10.1016/J.Schres.2011.11.001  0.43
2012 Johnson EB, Wilson J, Poh J, Yaakub S, Dorairaj K, Rapisarda A, Chee M, Chong SA, Subramaniam M, Keefe R, Kraus M, Keong JLC, Bong YL, Adcock RA. Midbrain modulation of hippocampus dependent learning in Singaporeans at ultra high risk for the development of schizophrenia F1000research. 3. DOI: 10.7490/F1000Research.1090638.1  0.31
2012 Keefe RSE, Kraus MS. Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia American Journal of Psychiatry. 169: 354-357. DOI: 10.1176/appi.ajp.2012.12010042  0.396
2012 Uchida H, Sakurai H, Bies RR, Stroup S, Keefe RS, Suzuki T, Tsuboi T, Mimura M, Pollock BG, Mamo DC. Poster #218 DOPAMINE D2 RECEPTOR OCCUPANCY AND COGNITION IN SCHIZOPHRENIA: ANALYSIS OF THE CATIE DATA Schizophrenia Research. 136: S359. DOI: 10.1016/S0920-9964(12)71050-2  0.335
2012 Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M. Poster #199 CLINICAL TRIALS OF POTENTIAL COGNITIVE-ENHANCING DRUGS IN SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR? Schizophrenia Research. 136: S352. DOI: 10.1016/S0920-9964(12)71031-9  0.353
2012 Rapisarda A, Lim T, Lim M, Collinson S, Kraus M, Keefe R. Poster #163 APPLICABILITY OF THE MATRICS CONSENSUS COGNITIVE BATTERY IN SINGAPORE Schizophrenia Research. 136. DOI: 10.1016/S0920-9964(12)70477-2  0.381
2012 Harvey PD, Ruse S, Davis V, Solomon M, Keefe R. 14:30 COMPUTERIZED FUNCTIONAL CAPACITY ASSESSMENTIN SCHIZOPHRENIA: EVIDENCE FOR CONVERGENT VALIDITY Schizophrenia Research. 136: S78-S79. DOI: 10.1016/S0920-9964(12)70284-0  0.604
2011 Kerfoot KE, Rosenheck RA, Petrakis IL, Swartz MS, Keefe RSE, McEvoy JP, Stroup TS. Substance use and schizophrenia: Adverse correlates in the CATIE study sample Schizophrenia Research. 132: 177-182. PMID 21872443 DOI: 10.1016/j.schres.2011.07.032  0.313
2011 Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, Lieberman JA. Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophrenia Research. 130: 47-52. PMID 21561740 DOI: 10.1016/J.Schres.2011.04.012  0.328
2011 Sim K, Lee J, Subramaniam M, Liu JJ, Keefe R, Zhang XD, Lee TS, Chong SA. Integrated genetic and genomic approach in the SingaporeTranslational and Clinical Research in Psychosis Study: an overview. Early Intervention in Psychiatry. 5: 91-9. PMID 21535421 DOI: 10.1111/J.1751-7893.2011.00272.X  0.432
2011 Burdick KE, Goldberg TE, Cornblatt BA, Keefe RS, Gopin CB, Derosse P, Braga RJ, Malhotra AK. The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 1587-92. PMID 21451499 DOI: 10.1038/Npp.2011.36  0.469
2011 Krishnan RR, Kraus MS, Keefe RSE. Comprehensive model of how reality distortion and symptoms occur in schizophrenia: Could impairment in learning-dependent predictive perception account for the manifestations of schizophrenia? Psychiatry and Clinical Neurosciences. 65: 305-317. PMID 21447049 DOI: 10.1111/j.1440-1819.2011.02203.x  0.399
2011 Reise SP, Ventura J, Keefe RS, Baade LE, Gold JM, Green MF, Kern RS, Mesholam-Gately R, Nuechterlein KH, Seidman LJ, Bilder R. Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia. Psychological Assessment. 23: 245-61. PMID 21381848 DOI: 10.1037/A0021501  0.387
2011 Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophrenia Research. 127: 188-94. PMID 21277745 DOI: 10.1016/J.Schres.2011.01.004  0.55
2011 Krishnan RR, Fivaz M, Kraus MS, Keefe RS. Hierarchical temporal processing deficit model of reality distortion and psychoses. Molecular Psychiatry. 16: 129-44. PMID 21263440 DOI: 10.1038/mp.2010.63  0.417
2011 Kern RS, Gold JM, Dickinson D, Green MF, Nuechterlein KH, Baade LE, Keefe RS, Mesholam-Gately RI, Seidman LJ, Lee C, Sugar CA, Marder SR. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophrenia Research. 126: 124-31. PMID 21159492 DOI: 10.1016/J.Schres.2010.11.008  0.426
2011 Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biological Psychiatry. 69: 442-9. PMID 21145041 DOI: 10.1016/J.Biopsych.2010.09.052  0.467
2011 Keefe RSE, Kraus MS, Krishnan RR. Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia Neuropsychopharmacology. 36: 367-368. PMID 21116261 DOI: 10.1038/npp.2010.153  0.361
2011 Greenberg G, Rosenheck RA, Erickson SK, Desai RA, Stefanovics EA, Swartz M, Keefe RS, McEvoy J, Stroup TS. Criminal justice system involvement among people with schizophrenia. Community Mental Health Journal. 47: 727-36. PMID 21113799 DOI: 10.1007/s10597-010-9362-9  0.32
2011 Keefe RS. Missing the sweet spot disengagement in schizophrenia. Psychiatry (Edgmont (Pa. : Township)). 3: 36-41. PMID 20975816  0.446
2011 Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, Campbell EC, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. The Journal of Clinical Psychiatry. 72: 295-303. PMID 20816031 DOI: 10.4088/Jcp.09M05793Yel  0.303
2011 Segarra N, Bernardo M, Gutierrez F, Justicia A, Fernadez-Egea E, Allas M, Safont G, Contreras F, Gascon J, Soler-Insa PA, Menchon JM, Junque C, Keefe RSE. Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls European Psychiatry. 26: 69-73. PMID 20435446 DOI: 10.1016/J.Eurpsy.2009.11.001  0.492
2011 Sachs G, Winklbaur B, Jagsch R, Keefe RS. Validation of the German version of the brief assessment of cognition in Schizophrenia (BACS) - preliminary results. European Psychiatry : the Journal of the Association of European Psychiatrists. 26: 74-7. PMID 20427153 DOI: 10.1016/j.eurpsy.2009.10.006  0.418
2011 Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophrenia Bulletin. 37: 1209-17. PMID 20410237 DOI: 10.1093/Schbul/Sbq038  0.422
2011 Keefe RS, Vinogradov S, Medalia A, Silverstein SM, Bell MD, Dickinson D, Ventura J, Marder SR, Stroup TS. Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. Schizophrenia Bulletin. 37: 1057-65. PMID 20194249 DOI: 10.1093/Schbul/Sbq010  0.393
2011 Hurford IM, Marder SR, Keefe RS, Reise SP, Bilder RM. A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. Schizophrenia Bulletin. 37: 538-45. PMID 19776205 DOI: 10.1093/Schbul/Sbp095  0.416
2011 Targum SD, Keefe RS. Cognition and schizophrenia: is there a role for cognitive assessments in diagnosis and treatment? Psychiatry (Edgmont (Pa. : Township)). 5: 55-9. PMID 19724777  0.415
2011 Keefe RS. Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry : Official Journal of the World Psychiatric Association (Wpa). 7: 22-8. PMID 18458774 DOI: 10.1002/j.2051-5545.2008.tb00142.x  0.465
2011 Sarkisyan G, Gurovich I, Keefe R. Normative data for Russian population and standardization of the scale “Brief assessment of cognition in schizophrenia” European Psychiatry. 26: 434-434. DOI: 10.1016/S0924-9338(11)72141-1  0.441
2010 Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophrenia Research. 125: 161-8. PMID 21075600 DOI: 10.1016/J.Schres.2010.09.015  0.595
2010 Lamonica HM, Keefe RS, Harvey PD, Gold JM, Goldberg TE. Differential effects of emotional information on interference task performance across the life span. Frontiers in Aging Neuroscience. 2. PMID 20953250 DOI: 10.3389/Fnagi.2010.00141  0.312
2010 Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry. 71: 1475-81. PMID 20816042 DOI: 10.4088/JCP.09m05950gry  0.401
2010 Ascher-Svanum H, Nyhuis AW, Stauffer V, Kinon BJ, Faries DE, Phillips GA, Schuh K, Awad AG, Keefe R, Naber D. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Current Medical Research and Opinion. 26: 2403-10. PMID 20812791 DOI: 10.1185/03007995.2010.515900  0.46
2010 Ventura J, Reise SP, Keefe RS, Baade LE, Gold JM, Green MF, Kern RS, Mesholam-Gately R, Nuechterlein KH, Seidman LJ, Bilder RM. The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognition. Schizophrenia Research. 121: 24-31. PMID 20542412 DOI: 10.1016/J.Schres.2010.04.016  0.411
2010 Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, ... Keefe RS, et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Archives of General Psychiatry. 67: 578-88. PMID 20530007 DOI: 10.1016/J.Schres.2010.02.210  0.343
2010 Chia MY, Chan WY, Chua KY, Lee H, Lee J, Lee R, Lim C, Tay E, Woon PS, Keefe RS, Sim K. The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia. Psychiatry Research. 178: 33-8. PMID 20451258 DOI: 10.1016/j.psychres.2010.03.020  0.484
2010 Polanczyk G, Moffitt TE, Arseneault L, Cannon M, Ambler A, Keefe RS, Houts R, Odgers CL, Caspi A. Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort. Archives of General Psychiatry. 67: 328-38. PMID 20368509 DOI: 10.1001/Archgenpsychiatry.2010.14  0.317
2010 Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 1053-62. PMID 20090669 DOI: 10.1038/Npp.2009.211  0.543
2010 Reichenberg A, Caspi A, Harrington H, Houts R, Keefe RS, Murray RM, Poulton R, Moffitt TE. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. The American Journal of Psychiatry. 167: 160-9. PMID 20048021 DOI: 10.1176/Appi.Ajp.2009.09040574  0.414
2010 Keefe RSE. Neurocognition Antipsychotic Trials in Schizophrenia: the Catie Project. 97-119. DOI: 10.1017/CBO9780511712265.007  0.488
2010 Keefe R, Vinogradov S, Medalia A, Buckley P, Caroff S, D'Souza D, Harvey P, Graham K, Marder S, Miller D, Olson S, Patel J, Velligan D, Walker T, Haim A, et al. Feasibility Study Of Multi-Site Cognitive Remediation In The Schizophrenia Trials Network (Crstn) Schizophrenia Research. 117: 394-394. DOI: 10.1016/J.Schres.2010.02.712  0.481
2010 Kern RS, Gold JM, Dickinson D, Green MF, Nuechterlein KH, Keefe RS, Marder SR, Sugar CA. COGNITIVE DYSFUNCTION AND COMMUNITY FUNCTIONING IN SCHIZOPHRENIA: RESULTS FROM THE MATRICS PSYCHOMETRIC AND STANDARDIZATION STUDY (PASS) Schizophrenia Research. 117: 323-324. DOI: 10.1016/J.Schres.2010.02.551  0.423
2010 Geffen Y, Anand R, Keefe R, Davidson M. Results Of Phase 2B Eagle Trial; A Double Blind Placebo Control Study Evaluating The Efficacy And Safety Of Bl-1020, A Gaba Enhanced Antipsychotic For The Treatment Of Schizophrenia Schizophrenia Research. 117: 212-212. DOI: 10.1016/J.Schres.2010.02.296  0.428
2010 Reichenberg A, Caspi A, Harrington H, Houts R, Keefe R, Murray R, Poulton R, Moffitt T. Static And Dynamic Cognitive Deficits In Childhood Precede Adult Schizophrenia: A 30-Year Study Schizophrenia Research. 117: 175-175. DOI: 10.1016/J.Schres.2010.02.207  0.484
2010 Buchanan RW, Barch D, Csernansky J, Goff D, Gold J, Jarskog F, Javitt D, Keefe R, Lieberman J, McEvoy J, McMahon R, Marder S. MK-0777 FOR THE TREATMENT OF COGNITIVE IMPAIRMENTS IN PEOPLE WITH SCHIZOPHRENIA Schizophrenia Research. 117: 119. DOI: 10.1016/J.Schres.2010.02.053  0.523
2009 Lipkovich IA, Deberdt W, Csernansky JG, Sabbe B, Keefe RS, Kollack-Walker S. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. Bmc Psychiatry. 9: 44. PMID 19602273 DOI: 10.1186/1471-244X-9-44  0.438
2009 Kraus MS, Keefe RSE, Krishnan RKR. Memory-prediction errors and their consequences in schizophrenia Neuropsychology Review. 19: 336-352. PMID 19575296 DOI: 10.1007/s11065-009-9106-1  0.453
2009 Keefe RSE, Kraus MS. Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia Annals of the Academy of Medicine Singapore. 38: 414-419. PMID 19521641  0.401
2009 Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). The American Journal of Psychiatry. 166: 675-82. PMID 19369319 DOI: 10.1176/Appi.Ajp.2008.08060806  0.426
2009 Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW, Strauss JL, Naylor JC, Payne VM, Lieberman JA, Savitz AJ, Leimone LA, Dunn L, Porcu P, Morrow AL, et al. Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 1885-903. PMID 19339966 DOI: 10.1038/Npp.2009.26  0.352
2009 Sim K, Yang GL, Loh D, Poon LY, Sitoh YY, Verma S, Keefe R, Collinson S, Chong SA, Heckers S, Nowinski W, Pantelis C. White matter abnormalities and neurocognitive deficits associated with the passivity phenomenon in schizophrenia: a diffusion tensor imaging study. Psychiatry Research. 172: 121-7. PMID 19297135 DOI: 10.1016/J.Pscychresns.2009.02.003  0.417
2009 Krishnan RR, Keefe R, Kraus M. Schizophrenia is a disorder of higher order hierarchical processing Medical Hypotheses. 72: 740-744. PMID 19231093 DOI: 10.1016/J.Mehy.2008.12.039  0.47
2009 Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, Shianna KV, Yoon W, KasperaviciÅ«te D, Gennarelli M, Strittmatter WJ, Bonvicini C, Rossi G, Jayathilake K, Cola PA, ... ... Keefe RS, et al. A genome-wide investigation of SNPs and CNVs in schizophrenia. Plos Genetics. 5: e1000373. PMID 19197363 DOI: 10.1371/Journal.Pgen.1000373  0.333
2009 Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research. 107: 1-12. PMID 19027269 DOI: 10.1016/J.Schres.2008.10.011  0.314
2009 Kleinman L, Lieberman J, Dube S, Mohs R, Zhao Y, Kinon B, Carpenter W, Harvey PD, Green MF, Keefe RS, Frank L, Bowman L, Revicki DA. Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophrenia Research. 107: 275-85. PMID 19013769 DOI: 10.1016/J.Schres.2008.10.002  0.54
2009 Harvey PD, Keefe RS, Patterson TL, Heaton RK, Bowie CR. Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. Journal of Clinical and Experimental Neuropsychology. 31: 462-71. PMID 18720182 DOI: 10.1080/13803390802251386  0.479
2009 Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, Shianna KV, Yoon W, Kasperavičiūtė D, Gennarelli M, Strittmatter WJ, Bonvicini C, Rossi G, Jayathilake K, Cola PA, ... ... Keefe RSE, et al. Correction: A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia Plos Genetics. 5. DOI: 10.1371/Annotation/E0196Ebb-De40-453F-8F8C-791B126618Da  0.312
2009 Pinheiro AP, Keefe RSE, Skelly T, Olarte M, Leviel K, Lange LA, Lange EM, Stroup TS, Lieberman J, Sullivan Pf. Erratum: AKT1 and neurocognition in schizophrenia (Australian and New Zealand Journal of Psychiatry (2007) 41 (169-177)) Australian and New Zealand Journal of Psychiatry. 43. DOI: 10.1080/00048670903228991  0.338
2008 Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH. Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research. 105: 1-9. PMID 18774696 DOI: 10.1016/J.Schres.2008.07.008  0.386
2008 Keefe RSE, Harvey PD. Implementation considerations for multisite clinical trials with cognitive neuroscience tasks Schizophrenia Bulletin. 34: 656-663. PMID 18495645 DOI: 10.1093/Schbul/Sbn042  0.455
2008 Keefe RSE, Harvey PD, Goldberg TE, Gold JM, Walker TM, Kennel C, Hawkins K. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS) Schizophrenia Research. 102: 108-115. PMID 18495435 DOI: 10.1016/J.Schres.2008.03.024  0.61
2008 Lieberman JA, Drake RE, Sederer LI, Belger A, Keefe R, Perkins D, Stroup S. Science and recovery in schizophrenia. Psychiatric Services (Washington, D.C.). 59: 487-96. PMID 18451003 DOI: 10.1176/Ps.2008.59.5.487  0.489
2008 Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RS. Relationship of cognition and psychopathology to functional impairment in schizophrenia. The American Journal of Psychiatry. 165: 978-87. PMID 18450928 DOI: 10.1176/Appi.Ajp.2008.07111713  0.428
2008 Hill SK, Sweeney JA, Hamer RM, Keefe RS, Perkins DO, Gu H, McEvoy JP, Lieberman JA. Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. Journal of the International Neuropsychological Society : Jins. 14: 209-21. PMID 18282319 DOI: 10.1017/S1355617708080570  0.411
2008 Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. The American Journal of Psychiatry. 165: 203-13. PMID 18172019 DOI: 10.1176/Appi.Ajp.2007.07010042  0.427
2008 Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. The American Journal of Psychiatry. 165: 214-20. PMID 18172018 DOI: 10.1176/Appi.Ajp.2007.07010043  0.35
2008 Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Seidman LJ, Stover E, Marder SR. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. The American Journal of Psychiatry. 165: 221-8. PMID 18172017 DOI: 10.1176/Appi.Ajp.2007.07010089  0.359
2008 Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 1217-28. PMID 17625502 DOI: 10.1038/Sj.Npp.1301499  0.424
2008 Bratti I, Ventura J, Marder S, Reise S, Keefe R, Bilder R. PRACTICE AND LEARNING EFFECTS WITH NEUROPSYCHOLOGICAL BATTERIES IN PATIENTS WITH SCHIZOPHRENIA Schizophrenia Research. 102: 117. DOI: 10.1016/S0920-9964(08)70354-2  0.431
2008 Keefe R. The Cognitive Effects Of Risperidone, Olanzapine And Quetiapine In Patients With First Episode Psychosis Schizophrenia Research. 102: 54. DOI: 10.1016/S0920-9964(08)70170-1  0.46
2008 Stroup S, Lieberman J, McEvoy J, Swartz M, Davis S, Rosenheck R, Keefe R. Findings Of Phase 3 Of The Catie Schizophrenia Trial Schizophrenia Research. 102: 34-35. DOI: 10.1016/S0920-9964(08)70109-9  0.432
2007 Keefe RSE. Cognitive deficits in patients with schizophrenia: Effects and treatment Journal of Clinical Psychiatry. 68: 8-13. PMID 18284272  0.454
2007 Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry and Clinical Neurosciences. 61: 602-609. PMID 18081619 DOI: 10.1111/J.1440-1819.2007.01725.X  0.476
2007 Kraus MS, Keefe RSE. Cognition as an outcome measure in schizophrenia British Journal of Psychiatry. 191. PMID 18019044 DOI: 10.1192/bjp.191.50.s46  0.486
2007 Goff DC, Keefe R, Citrome L, Davy K, Krystal JH, Large C, Thompson TR, Volavka J, Webster EL. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. Journal of Clinical Psychopharmacology. 27: 582-9. PMID 18004124 DOI: 10.1097/Jcp.0B013E31815Abf34  0.478
2007 Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. The American Journal of Psychiatry. 164: 1061-71. PMID 17606658 DOI: 10.1176/Ajp.2007.164.7.1061  0.359
2007 Keefe RSE, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophrenia Bulletin. 33: 912-920. PMID 17567627 DOI: 10.1093/schbul/sbm046  0.46
2007 Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry. 64: 633-47. PMID 17548746 DOI: 10.1001/Archpsyc.64.6.633  0.481
2007 Pinheiro AP, Keefe RS, Skelly T, Olarte M, Leviel K, Lange LA, Lange EM, Stroup TS, Lieberman J, Sullivan PF. AKT1 and neurocognition in schizophrenia. The Australian and New Zealand Journal of Psychiatry. 41: 169-77. PMID 17464696 DOI: 10.1080/00048670601109956  0.362
2007 Bralet MC, Falissard B, Neveu X, Lucas-Ross M, Eskenazi AM, Keefe RS. Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients. European Psychiatry : the Journal of the Association of European Psychiatrists. 22: 365-70. PMID 17434715 DOI: 10.1016/j.eurpsy.2007.02.001  0.473
2007 Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American Journal of Psychiatry. 164: 428-36. PMID 17329467 DOI: 10.1176/Ajp.2007.164.3.428  0.352
2007 Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. The American Journal of Psychiatry. 164: 415-27. PMID 17329466 DOI: 10.1176/Ajp.2007.164.3.415  0.355
2007 Pandina GJ, Bilder R, Harvey PD, Keefe RSE, Aman MG, Gharabawi G. Risperidone and Cognitive Function in Children With Disruptive Behavior Disorders Biological Psychiatry. 62: 226-234. PMID 17210137 DOI: 10.1016/J.Biopsych.2006.09.036  0.429
2007 Lipkovich I, Kollack-Walker S, Kinon B, Stauffer V, Ascher-Svanum H, Keefe R. Poster Abstract #3: Cognitive Status of Patients With Schizophrenia as Modulator or Mediator of Functional Outcome Neurotherapeutics. 4: 725-726. DOI: 10.1016/J.Nurt.2007.03.007  0.512
2006 Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American Journal of Psychiatry. 163: 2080-9. PMID 17151158 DOI: 10.1176/Ajp.2006.163.12.2080  0.312
2006 Chwastiak LA, Rosenheck RA, McEvoy JP, Keefe RS, Swartz MS, Lieberman JA. Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatric Services (Washington, D.C.). 57: 1102-9. PMID 16870960 DOI: 10.1176/Ps.2006.57.8.1102  0.353
2006 Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatric Services (Washington, D.C.). 57: 1094-101. PMID 16870959 DOI: 10.1176/PS.2006.57.8.1094  0.314
2006 Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 2033-46. PMID 16641947 DOI: 10.1038/Sj.Npp.1301072  0.59
2006 Woodward TS, Menon M, Hu X, Keefe RS. Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring. Schizophrenia Research. 85: 106-12. PMID 16626938 DOI: 10.1016/J.Schres.2006.03.008  0.366
2006 Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. The American Journal of Psychiatry. 163: 611-22. PMID 16585435 DOI: 10.1176/Appi.Ajp.163.4.611  0.359
2006 McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. The American Journal of Psychiatry. 163: 600-10. PMID 16585434 DOI: 10.1176/Appi.Ajp.163.4.600  0.339
2006 Keefe RS, Poe M, Walker TM, Kang JW, Harvey PD. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. The American Journal of Psychiatry. 163: 426-32. PMID 16513863 DOI: 10.1176/Appi.Ajp.163.3.426  0.584
2006 Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, Lieberman J. Barriers to employment for people with schizophrenia. The American Journal of Psychiatry. 163: 411-7. PMID 16513861 DOI: 10.1176/Appi.Ajp.163.3.411  0.462
2006 Keefe RS, Poe M, Walker TM, Harvey PD. The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. Journal of Clinical and Experimental Neuropsychology. 28: 260-9. PMID 16484097 DOI: 10.1080/13803390500360539  0.587
2006 Chwastiak LA, Rosenheck RA, McEvoy JP, Keefe RS, Swartz MS, Lieberman JA. Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatric Services. 57: 1102-1109. DOI: 10.1176/Appi.Ps.57.8.1102  0.319
2006 Keefe R. C.07.02 Neurocognitive efficacy in patients with chronic schizophrenia European Neuropsychopharmacology. 16: S577. DOI: 10.1016/S0924-977X(06)70830-6  0.32
2006 Atkins AS, Khan A, Kelly SE, Abraham C, Ulshen D, Plassman BL, Welsh-Bohmer KA, Keefe RS. P4-340: PERFORMANCE-BASED ASSESSMENT OF IADL FUNCTIONING IN MCI AND MILD AD USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT): A PILOT STUDY Alzheimer's & Dementia. 14: P1597-P1597. DOI: 10.1016/J.Jalz.2018.07.163  0.585
2005 Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, Lieberman J. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research. 80: 1-8. PMID 16182516 DOI: 10.1016/J.Schres.2005.08.007  0.464
2005 Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, Lieberman JA. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophrenia Research. 80: 33-43. PMID 16171976 DOI: 10.1016/J.Schres.2005.07.034  0.404
2005 Artiola I Fortuny L, Garolera M, Hermosillo Romo D, Feldman E, Fernández Barillas H, Keefe R, Lemaître MJ, Ortiz Martín A, Mirsky A, Monguió I, Morote G, Parchment S, Parchment LJ, Da Pena E, Politis DG, et al. Research with spanish-speaking populations in the United States: lost in the translation. A commentary and a plea. Journal of Clinical and Experimental Neuropsychology. 27: 555-64. PMID 16019632 DOI: 10.1080/13803390490918282  0.327
2005 Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, Nuechterlein KH, Laughren T, Levin R, Stover E, Fenton W, Marder SR. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophrenia Bulletin. 31: 5-19. PMID 15888422 DOI: 10.1093/Schbul/Sbi020  0.338
2005 Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry. 62: 361-70. PMID 15809403 DOI: 10.1001/Archpsyc.62.4.361  0.465
2005 Keefe RSE, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia Biological Psychiatry. 57: 688-691. PMID 15780858 DOI: 10.1016/j.biopsych.2005.01.003  0.453
2004 Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biological Psychiatry. 56: 301-7. PMID 15336511 DOI: 10.1016/J.Biopsych.2004.06.023  0.421
2004 Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophrenia Research. 68: 283-97. PMID 15099610 DOI: 10.1016/J.Schres.2003.09.011  0.615
2004 Harvey PD, Green MF, Keefe RS, Velligan DI. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. The Journal of Clinical Psychiatry. 65: 361-72. PMID 15096076 DOI: 10.4088/Jcp.V65N0312  0.581
2004 Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophrenia Research. 67: 115-22. PMID 14984870 DOI: 10.1016/J.Schres.2003.08.007  0.336
2004 Sethuraman G, Ahmed S, Rock S, Young C, Marquez E, Purdon S, Keefe R. P.2.137 Can the PANSS cognitive factor be a validsurrogate for neurocognon in schizophrenia? European Neuropsychopharmacology. 14: S292-S293. DOI: 10.1016/S0924-977X(04)80357-2  0.42
2003 Keefe RS, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY, Gold JM, Sano M. Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophrenia Bulletin. 29: 45-55. PMID 12908660 DOI: 10.1093/Oxfordjournals.Schbul.A006990  0.539
2003 Keefe RSE, Poe MP, McEvoy JP, Vaughan A. Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications Psychopharmacology. 169: 383-389. PMID 12759802 DOI: 10.1007/s00213-003-1476-0  0.345
2003 Morey RA, Emberger K, Inan S, McClure R, Lieberman J, Keefe R, McCarthy G, Belger A. Functional MRI assessment of atypical and conventional antipsychotic effects on cognitive function in schizophrenia patients Schizophrenia Research. 60: 229. DOI: 10.1016/S0920-9964(03)81212-4  0.54
2003 Breier A, Keefe RS, Young CA, Purdon SE, Gold JM, Davis KL. A one-year double-blind comparison of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in patients with schizophrenia Schizophrenia Research. 60: 274-275. DOI: 10.1016/S0920-9964(03)80434-6  0.525
2003 Hawkins KA, McGlashan T, Keefe R, Christensen B, Addington J, Marquez E, Breier A. Neuropsychological status of the first-episode prodrome Schizophrenia Research. 60: 4. DOI: 10.1016/S0920-9964(03)80008-7  0.349
2002 Keefe RS, Arnold MC, Bayen UJ, McEvoy JP, Wilson WH. Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources. Schizophrenia Research. 57: 51-67. PMID 12165376 DOI: 10.1016/S0920-9964(01)00306-1  0.309
2002 Keefe R. Compliance, cognition and psychosis: first episode European Psychiatry. 17: 12. DOI: 10.1016/S0924-9338(02)80056-6  0.333
2001 Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment American Journal of Psychiatry. 158: 176-184. PMID 11156796 DOI: 10.1176/Appi.Ajp.158.2.176  0.607
2000 Roitman SE, Mitropoulou V, Keefe RS, Silverman JM, Serby M, Harvey PD, Reynolds DA, Mohs RC, Siever LJ. Visuospatial working memory in schizotypal personality disorder patients. Schizophrenia Research. 41: 447-55. PMID 10728721 DOI: 10.1016/S0920-9964(99)00085-7  0.508
1999 Keefe RS, Arnold MC, Bayen UJ, Harvey PD. Source monitoring deficits in patients with schizophrenia; a multinomial modelling analysis. Psychological Medicine. 29: 903-14. PMID 10473317 DOI: 10.1017/S0033291799008673  0.434
1999 Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis Schizophrenia Bulletin. 25: 201-222. PMID 10416727 DOI: 10.1093/Oxfordjournals.Schbul.A033374  0.454
1999 Keefe RSE, Bollini AM, Silva SG. Do Novel Antipsychotics Improve Cognition? A Report of a Meta-Analysis Psychiatric Annals. 29: 623-629. DOI: 10.3928/0048-5713-19991101-08  0.306
1998 Davis KL, Buchsbaum MS, Shihabuddin L, Spiegel-Cohen J, Metzger M, Frecska E, Keefe RS, Powchik P. Ventricular enlargement in poor-outcome schizophrenia. Biological Psychiatry. 43: 783-93. PMID 9611667 DOI: 10.1016/S0006-3223(97)00553-2  0.429
1998 Keefe R, Courtney M, Bayan U, Harvey P, McEvoy J. Does autonoetic agnosia underlie specific psychotic symptoms in schizophrenia? Schizophrenia Research. 29: 36. DOI: 10.1016/S0920-9964(97)88379-X  0.537
1997 Roitman SE, Keefe RS, Harvey PD, Siever LJ, Mohs RC. Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia. Schizophrenia Research. 26: 139-46. PMID 9323344 DOI: 10.1016/S0920-9964(97)00044-3  0.482
1997 Roitman SE, Cornblatt BA, Bergman A, Obuchowski M, Mitropoulou V, Keefe RS, Silverman JM, Siever LJ. Attentional functioning in schizotypal personality disorder. The American Journal of Psychiatry. 154: 655-60. PMID 9137121 DOI: 10.1176/AJP.154.5.655  0.333
1997 Keefe RS, Silverman JM, Mohs RC, Siever LJ, Harvey PD, Friedman L, Roitman SE, DuPre RL, Smith CJ, Schmeidler J, Davis KL. Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia. Archives of General Psychiatry. 54: 169-76. PMID 9040285 DOI: 10.1001/Archpsyc.1997.01830140081014  0.631
1997 Harvey PD, Keefe RSE. Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment Cns Spectrums. 2: 41-55. DOI: 10.1017/S1092852900005034  0.599
1997 Harvey PD, Keefe RSE. Cognitive Impairment in Schizophrenia and Implications of Atypical Neuroleptic Treatment Cns Spectrums. 2: 41-55. DOI: 10.1017/S1092852900005034  0.599
1997 Keefe RS, Courtney M, McEvoy JM. Self-monitoring deficits in schizophrenia: Autonoetic agnosia Schizophrenia Research. 24: 110. DOI: 10.1016/S0920-9964(97)82306-7  0.329
1996 Harvey PD, Davidson M, White L, Keefe RS, Hirschowitz J, Mohs RC, Davis KL. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. Biological Psychiatry. 40: 755-60. PMID 8894068 DOI: 10.1016/0006-3223(95)00486-6  0.606
1996 Epstein JI, Keefe RS, Roitman SL, Harvey PD, Mohs RC. Impact of neuroleptic medications on continuous performance test measures in schizophrenia. Biological Psychiatry. 39: 902-5. PMID 8860194 DOI: 10.1016/0006-3223(95)00588-9  0.531
1996 Trestman RL, Keefe RS, Mitropoulou V, Harvey PD, deVegvar ML, Lees-Roitman S, Davidson M, Aronson A, Silverman J, Siever LJ. Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Research. 59: 127-36. PMID 8771227 DOI: 10.1016/0165-1781(95)02709-2  0.538
1996 Keefe RS, Frescka E, Apter SH, Davidson M, Macaluso JM, Hirschowitz J, Davis KL. Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. The American Journal of Psychiatry. 153: 806-11. PMID 8633694 DOI: 10.1176/Ajp.153.6.806  0.536
1996 Keefe RSE, Cornblatt BA. Schizophrenia: All Pathways to Symptoms Pass Through Cognitive Deficits? Contemporary Psychology: a Journal of Reviews. 41: 900-902. DOI: 10.1037/003129  0.444
1996 Keefe R, Roitman S, Dupre R, Harvey P. Laboratory and clinical tests of spatial working memory Schizophrenia Research. 18: 208-209. DOI: 10.1016/0920-9964(96)85644-1  0.327
1996 Harvey PD, Keefe RSE, Mitroupolou V, DuPre R, Roitman SL, Mohs RC, Siever LJ. Information-processing markers of vulnerability to schizophrenia: Performance of patients with schizotypal and nonschizotypal personality disorders Psychiatry Research. 60: 49-56. DOI: 10.1016/0165-1781(95)02764-5  0.471
1995 Keefe RS, Roitman SE, Harvey PD, Blum CS, DuPre RL, Prieto DM, Davidson M, Davis KL. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophrenia Research. 17: 25-33. PMID 8541247 DOI: 10.1016/0920-9964(95)00027-J  0.568
1995 Davidson M, Keefe RSE. Cognitive impairment as a target for pharmacological treatment in schizophrenia Schizophrenia Research. 17: 123-129. PMID 8541245 DOI: 10.1016/0920-9964(95)00037-M  0.418
1995 Davidson M, Harvey PD, Powchik P, Parrella M, White L, Knobler HY, Losonczy MF, Keefe RS, Katz S, Frecska E. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. The American Journal of Psychiatry. 152: 197-207. PMID 7840352 DOI: 10.1176/Ajp.152.2.197  0.483
1995 Keefe RSE. The contribution of neuropsychology to psychiatry American Journal of Psychiatry. 152: 6-15. PMID 7802121 DOI: 10.1176/AJP.152.1.6  0.349
1995 Yehuda R, Keefe RS, Harvey PD, Levengood RA, Gerber DK, Geni J, Siever LJ. Learning and memory in combat veterans with posttraumatic stress disorder. The American Journal of Psychiatry. 152: 137-9. PMID 7802106 DOI: 10.1176/Ajp.152.1.137  0.379
1995 Keefe RS, Lees Roitman S, Dupre RL, Harvey PD, Davis KL, Mohs RC. The relationship between working memory deficits and other measures sensitive to prefrontal dysfunction Schizophrenia Research. 15: 123. DOI: 10.1016/0920-9964(95)95378-M  0.504
1995 Siever LJ, Trestman RL, Siegel BV, Losonczy M, Mitropoulou V, Silverman J, Keefe R, Mohs R, Buchsbaum M, Davis KL. Neuroimaging, neurobiological, and neuropsychological abnormalities in SPD: Implications for a model of the schizophrenia spectrum Schizophrenia Research. 15: 99. DOI: 10.1016/0920-9964(95)95307-U  0.591
1995 White L, Parrella M, Harvey PD, Keefe R, Davidson M. Influence of neuroleptics on symptom structure in schizophrenia Schizophrenia Research. 15: 23-24. DOI: 10.1016/0920-9964(95)95086-O  0.58
1994 Keefe RS, Silverman JM, Roitman SE, Harvey PD, Duncan MA, Alroy D, Siever LJ, Davis KL, Mohs RC. Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests. Psychiatry Research. 53: 1-12. PMID 7991726 DOI: 10.1016/0165-1781(94)90091-4  0.627
1994 Kahn RS, Harvey PD, Davidson M, Keefe RS, Apter S, Neale JM, Mohs RC, Davis KL. Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophrenia Research. 11: 217-24. PMID 7514887 DOI: 10.1016/0920-9964(94)90015-9  0.637
1994 Frecska E, Losonczy M, Keefe R, Apter S, Davidson M, Mohs R, Davis K. Age dependent change of ventricular measures in schizophrenia: Cross-sectional analysis Biological Psychiatry. 35: 704-705. DOI: 10.1016/0006-3223(94)90980-6  0.449
1994 Apter S, Keefe R, Hirschowitz J, Davidson M, Macaluso J, Amato R, Davis K. Longitudinal classification in schizophrenia: The relationship between kraepelinian and deficit syndrome subtypologies Biological Psychiatry. 35: 695. DOI: 10.1016/0006-3223(94)90944-X  0.514
1994 Epstein J, Keefe R, Lees Roitman S, Harvey P, Davidson M, Siever L, Mohs R. Neuroleptic effects on CPT and eye tracking in schizophrenia Biological Psychiatry. 35: 674. DOI: 10.1016/0006-3223(94)90872-9  0.473
1994 Cornblatt B, Obuchowski M, Schnur D, O'Brien J, Reich M, Wolf L, Futrovsky L, Keefe R, Osgood G. Adolescent-onset psychosis and the schizophrenia spectrum Biological Psychiatry. 35: 660. DOI: 10.1016/0006-3223(94)90821-4  0.421
1994 Keefe R, Blum C, Roitman S, Harvey P, Davidson M, Mohs R, Davis K. Working memory dysfunction in Kraepelinian schizophrenics Biological Psychiatry. 35: 660. DOI: 10.1016/0006-3223(94)90820-6  0.474
1993 Siever LJ, Kalus OF, Keefe RS. The Boundaries of Schizophrenia Psychiatric Clinics of North America. 16: 217-244. DOI: 10.1016/S0193-953X(18)30171-0  0.319
1993 Frecska E, Losonczy M, Keefe R, Silverman J, Davidson M, Davis K. The characteristics of poor outcome, ‘Kraepelinian’ schizophrenia European Neuropsychopharmacology. 3: 400. DOI: 10.1016/0924-977X(93)90193-P  0.495
1993 Keefe R, Lees S, Merhige D, Blum C, Harvey P, Davis K, Mohs R. Visuospatial working memory deficits in schizophrenia Schizophrenia Research. 9: 179-180. DOI: 10.1016/0920-9964(93)90355-M  0.489
1992 Keefe RS, Harvey PD, Lenzenweger MF, Davidson M, Apter SH, Schmeidler J, Mohs RC, Davis KL. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms. Psychiatry Research. 44: 153-65. PMID 1480680 DOI: 10.1016/0165-1781(92)90049-9  0.562
1992 Harvey PD, Lenzenweger MF, Keefe RS, Pogge DL, Serper MR, Mohs RC. Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: formal thought disorder. Psychiatry Research. 44: 141-51. PMID 1480679 DOI: 10.1016/0165-1781(92)90048-8  0.398
1992 Davidson M, Kahn RS, Stern RG, Harvey PD, Keefe R, Knott P, Apter S, Webster L, Davis KL. Measurements of plasma homovanillic acid in schizophrenic patients. Clinical Neuropharmacology. 521A-522A. PMID 1354058 DOI: 10.1097/00002826-199201001-00271  0.523
1992 Frecska E, Losonczy MF, Keefe RSE, Silverman JM, Davidson M, Davis KL. Characteristics Of Poor Outcome Schizophrenia Clinical Neuropharmacology. 15. DOI: 10.1097/00002826-199202001-00170  0.495
1991 Keefe RS, Lobel DS, Mohs RC, Silverman JM, Harvey PD, Davidson M, Losonczy MF, Davis KL. Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms. Schizophrenia Research. 4: 71-9. PMID 2039764 DOI: 10.1016/0920-9964(91)90026-N  0.529
1991 Keefe RS, Silverman JM, Siever LJ, Cornblatt BA. Refining phenotype characterization in genetic linkage studies of schizophrenia Social Biology. 38: 197-218. PMID 1801201 DOI: 10.1080/19485565.1991.9988788  0.393
1991 Harvey P, Davidson M, Mohs R, Keefe R, Moskowitz J, Knott P, Duffelmeyer M. Plasma HVA correlates of attentional performance in unmedicated schizophrenics Schizophrenia Research. 4: 345-346. DOI: 10.1016/0920-9964(91)90258-S  0.34
1991 Frecska E, Losonczy M, Keefe R, Silverman J, Davidson M, Harvey P, McQueeney R, Lobel D, Apter S, Davis K. Kraepelinian schizophrenia: A replication in an independent sample Schizophrenia Research. 4: 257. DOI: 10.1016/0920-9964(91)90108-4  0.496
1990 Siever LJ, Silverman JM, Horvath TB, Klar H, Coccaro E, Keefe RS, Pinkham L, Rinaldi P, Mohs RC, Davis KL. Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients. Archives of General Psychiatry. 47: 634-40. PMID 2360857 DOI: 10.1001/Archpsyc.1990.01810190034005  0.445
1990 Siever LJ, Keefe R, Bernstein DP, Coccaro EF, Klar HM, Zemishlany Z, Peterson AE, Davidson M, Mahon T, Horvath T, Mohs R. Eye tracking impairment in clinically identified patients with schizotypal personality disorder American Journal of Psychiatry. 147: 740-745. PMID 2343917 DOI: 10.1176/Ajp.147.6.740  0.378
1990 Harvey PD, Keefe RS, Moskowitz J, Putnam KM, Mohs RC, Davis KL. Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals. Psychiatry Research. 33: 179-88. PMID 2243895 DOI: 10.1016/0165-1781(90)90072-D  0.539
1989 Keefe RS, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Horvath TB, Davis KL. Premorbid sociosexual functioning and long-term outcome in schizophrenia. The American Journal of Psychiatry. 146: 206-11. PMID 2912262 DOI: 10.1176/AJP.146.2.206  0.51
1989 Keefe RS, Siever LJ, Mohs RC, Peterson AE, Mahon TR, Bergman RL, Davis KL. Eye tracking, schizophrenic symptoms, and schizotypal personality disorder. European Archives of Psychiatry and Neurological Sciences. 239: 39-42. PMID 2792157 DOI: 10.1007/BF01739742  0.413
1989 Silverman JM, Keefe RSE, Mohs RC, Davis KL. A study of the reliability of the family history method in genetic studies of Alzheimer disease. Alzheimer Disease & Associated Disorders. 3: 218-223. DOI: 10.1097/00002093-198900000-00004  0.326
1989 Silverman JM, Mohs RC, Siever LJ, Keefe RSE, Schear S, Davis KL. Using family history screening for linkage studies in schizophrenia Biological Psychiatry. 25. DOI: 10.1016/0006-3223(89)91776-9  0.456
1989 Siever LJ, Coccaro EF, Silverman J, Keefe R, Klar H, Davis KL. Biologic markers for personality disorders: A dimensional approach Biological Psychiatry. 25: A140. DOI: 10.1016/0006-3223(89)91769-1  0.381
1989 Keefe RS, Harvey PD, Bergman R, Mohs RC, Davis KL. State and trait components of negative symptoms within schizophrenic patients Biological Psychiatry. 25: A105. DOI: 10.1016/0006-3223(89)91698-3  0.525
1989 Keefe RSE, Siever LJ, Silverman JM, Mohs RC, Davis KL. symptom correlates of poor eye tracking in patients with schizotypal personality disorder and relatives of schizophrenic probands Biological Psychiatry. 25. DOI: 10.1016/0006-3223(89)91693-4  0.381
1989 Keefe RSE, Mohs RC, Siever LJ, Silverman JM, Harvey PD, Brenin DS, Davis KL. Relations among eye tracking, CPT, and backward masking deficits in schizophrenic patients and their relatives Biological Psychiatry. 25. DOI: 10.1016/0006-3223(89)91692-2  0.496
1987 Silverman JM, Mohs RC, Davidson M, Losonczy MF, Keefe RS, Breitner JC, Sorokin JE, Davis KL. Familial schizophrenia and treatment response. The American Journal of Psychiatry. 144: 1271-6. PMID 3661762 DOI: 10.1176/Ajp.144.10.1271  0.529
1987 Keefe RS, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Kendler KS, Horvath TB, Nora R, Davis KL. Characteristics of very poor outcome schizophrenia. The American Journal of Psychiatry. 144: 889-95. PMID 3605400 DOI: 10.1176/Ajp.144.7.889  0.529
1987 Davidson M, Keefe RS, Mohs RC, Siever LJ, Losonczy MF, Horvath TB, Davis KL. L-dopa challenge and relapse in schizophrenia. The American Journal of Psychiatry. 144: 934-8. PMID 2886063 DOI: 10.1176/AJP.144.7.934  0.385
Show low-probability matches.